My assessment has 3 categories, the product, company, and stock.
The Product:
I think the GluCurve Pet CGM is quite ingenious, I have talked to multiple veterinarians and diabetic pet owners and they all say the same thing. A pet CGM is desperately needed because you cant check sugar levels on cats or dogs using a lancet, meter, and test strips. Without a CGM its a guessing game, that's why using human CGMs off label from a pharmacy has become so popular. ALRT is capitalizing on a unique opportunity because they already have a diabetes platform in place for humans, they just had to modify it for animals. By doing so they solve all the problems of using a human CGM because they offer animal specific software to vets and pet owners, sell directly to vets, and support the product. Human CGMs have human software for human patient use, have to be prescribed by a pharmacy, and offer no support for animal use. ALRT is literally selling a one of a kind product to a market that desperately wants it with no real competition.
The Company:
I have incredible respect for the CEO Sidney Chan (the company), most CEOs go public on the OTC markets to sell toxic dilution and rip off shareholders... But Sidney has funded the company himself to the tune of over $20,000,000. I don't think people appreciate that he could have let the company go bankrupt at any time and gone private but he didn't. He could of also sold toxic dilution to pay for expenses but he didn't do that either. Instead he has funded the company himself and through his or his family's trust and backed it up with options to buy common shares as high as .05 each if I remember correctly. That means for him to win, we all have to win.
The Stock:
Because all of us have been invested in ALRT for years I think we have a jaded view where many feel like they are owed a huge return and have lost patience with the stock so the delays this year have killed the excitement. But reading the past 3 PRs from December, June, and August makes me extremely excited. Every PR the sales value of the order goes up, they are launching in Canada direct to clinics at higher margins, and they are relaunching in the US and EU through Covetrus shortly after. They have a better CGM, better manufacturer, and obviously huge demand. Clearly they have had manufacturing issues that have caused delays, but that is outside of their control so I don't blame ALRT for that and it doesn't change my excitement or long term view. When all sorted, the GluCurve seems like a cash cow and the stock price will reflect that in time regardless of current price. In my opinion, the current price is a huge buying opportunity right before they achieve success. I'm not worried about day to day price because if it triples tomorrow I would not sell a share. I'm looking long term for life changing returns not short term for a double up.
I am as bullish on ALRT as I have ever been and I am more confident in the company then ever because I see progress and perseverance and it comes at the CEOs expense not us shareholders. I have no doubt the shareprice will be significantly higher soon so weather that takes a few weeks or a few months I'm not worried about it.
Bullish
